Skip to main content
Clinical Trials/ACTRN12605000365662
ACTRN12605000365662
Completed
Phase 3

A pilot study to evaluate the potential roles for the topical application of aromatherapy essential oils in the modulation of immune function in healthy individuals

Sharon Kepper Aromatherapy: Fragrantia Investments0 sites20 target enrollmentSeptember 12, 2005

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Immune function
Sponsor
Sharon Kepper Aromatherapy: Fragrantia Investments
Enrollment
20
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 12, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Male

Investigators

Sponsor
Sharon Kepper Aromatherapy: Fragrantia Investments

Eligibility Criteria

Inclusion Criteria

  • Willing to comply with study protocols. The smokers must consume 10 cigarettes per day, and have done so for at least a year. The non\-smokers must have never smoked.

Exclusion Criteria

  • Factors resulting in exclusion include: any significant medical problem or chronic illness, including the findings on assessment of:o BMI \>30 or \<18, o undiagnosed hypertension oro pulse irregularities consistent with pathological cardiac dysrhythmia such as atrial fibrillationHistory of allergies to fragrances, current or recent dermatitis, regular use of medications, vitamin or supplement consumption, alcohol intake of more than 7 standard drinks per week or greater than 4 on heaviest day, high levels of exercise (extreme strenuous exercise for over 60 mins \>twice per week) Recreational drug use, any acute illness or infection in the preceding 2 weeks.

Outcomes

Primary Outcomes

Not specified

Similar Trials